Risk Factor and Outcome of Candidemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01249313|
Recruitment Status : Unknown
Verified June 2011 by China Medical University Hospital.
Recruitment status was: Not yet recruiting
First Posted : November 29, 2010
Last Update Posted : June 27, 2011
Candidemia is the fourth leading cause of hospital-acquired infection in USA. In CMUH, it caused 9% hospital-acquired bloodstream infection in 2008 and 2009. In addition to increased mortality, candidemia also increased hospital stay and cost. There is a trend of increased cases of candidemia in recent years in CMUH. Early empirical and target treatment can reduce mortality and shortened length of hospital stay.
In the past, most prior studies in Taiwan dealt with risk factors for mortality rather than for candidemia and also focused at in vitro susceptibility to antifungal agents. In this study, the investigators hope to analyze the candidemic cases from 2003 to 2009, estimated 1000 cases. There were some rare Candida species. Therefore, the investigators hope to do case study for these diseases to provide the epidemiology of candidemia in CMUH. The result can help clinician in predicting the disease and its outcome. Besides, it also provides the epidemiology of candidemia in mid-Taiwan.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Study Start Date :||September 2011|
|Estimated Primary Completion Date :||April 2012|
|Estimated Study Completion Date :||December 2012|